Cargando…
Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice
BACKGROUND: Bacteremia-induced sepsis is a leading cause of mortality in intensive care units. To control a bacterial infection, an immune response is required, but this response might contribute to organ failure. Kidneys are one of the main organs affected by bacteremia. Combination therapies with...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885212/ https://www.ncbi.nlm.nih.gov/pubmed/33588861 http://dx.doi.org/10.1186/s12951-021-00789-5 |
_version_ | 1783651560035713024 |
---|---|
author | Liao, Chia-Chih Yu, Huang-Ping Yang, Shih-Chun Alalaiwe, Ahmed Dai, You-Shan Liu, Fu-Chao Fang, Jia-You |
author_facet | Liao, Chia-Chih Yu, Huang-Ping Yang, Shih-Chun Alalaiwe, Ahmed Dai, You-Shan Liu, Fu-Chao Fang, Jia-You |
author_sort | Liao, Chia-Chih |
collection | PubMed |
description | BACKGROUND: Bacteremia-induced sepsis is a leading cause of mortality in intensive care units. To control a bacterial infection, an immune response is required, but this response might contribute to organ failure. Kidneys are one of the main organs affected by bacteremia. Combination therapies with antibacterial and anti-inflammatory effects may be beneficial in treating bacteremia. This study aimed to develop nanostructured lipid carriers (NLCs) loaded with ciprofloxacin and rolipram that exert a combination of anti-methicillin-resistant Staphylococcus aureus (MRSA) and anti-inflammatory effects. Retinol was incorporated into the nanoparticles to transport retinol-binding protein 4 (RBP4) to the kidneys, which abundantly express RBP receptors. The NLCs were fabricated by high-shear homogenization and sonication, and neutrophils were used as a model to assess their anti-inflammatory effects. Mice were injected with MRSA to establish a model of bacteremia with organ injury. RESULTS: The mean nanoparticle size and zeta potential of the NLCs were 171 nm and − 39 mV, respectively. Ciprofloxacin (0.05%, w/v) and rolipram (0.02%) achieved encapsulation percentages of 88% and 96%, respectively, in the nanosystems. The minimum bactericidal concentration of free ciprofloxacin against MRSA increased from 1.95 to 15.63 µg/ml when combined with rolipram, indicating a possible drug-drug interaction that reduced the antibacterial effect. Nanoparticle inclusion promoted the anti-MRSA activity of ciprofloxacin according to time-kill curves. The NLCs were found to be largely internalized into neutrophils and exhibited superior superoxide anion inhibition than free drugs. Retinol incorporation into the nanocarriers facilitated their efficient targeting to the kidneys. The NLCs significantly mitigated MRSA burden and elastase distribution in the organs of MRSA-infected animals, and the greatest inhibition was observed in the kidneys. Bacterial clearance and neutrophil infiltration suppression attenuated the bacteremia-induced cytokine overexpression, leading to an improvement in the survival rate from 22% to 67%. CONCLUSIONS: The dual role of our NLCs endowed them with greater efficacy in treating MRSA bacteremia than that of free drugs. [Image: see text] |
format | Online Article Text |
id | pubmed-7885212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78852122021-02-17 Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice Liao, Chia-Chih Yu, Huang-Ping Yang, Shih-Chun Alalaiwe, Ahmed Dai, You-Shan Liu, Fu-Chao Fang, Jia-You J Nanobiotechnology Research BACKGROUND: Bacteremia-induced sepsis is a leading cause of mortality in intensive care units. To control a bacterial infection, an immune response is required, but this response might contribute to organ failure. Kidneys are one of the main organs affected by bacteremia. Combination therapies with antibacterial and anti-inflammatory effects may be beneficial in treating bacteremia. This study aimed to develop nanostructured lipid carriers (NLCs) loaded with ciprofloxacin and rolipram that exert a combination of anti-methicillin-resistant Staphylococcus aureus (MRSA) and anti-inflammatory effects. Retinol was incorporated into the nanoparticles to transport retinol-binding protein 4 (RBP4) to the kidneys, which abundantly express RBP receptors. The NLCs were fabricated by high-shear homogenization and sonication, and neutrophils were used as a model to assess their anti-inflammatory effects. Mice were injected with MRSA to establish a model of bacteremia with organ injury. RESULTS: The mean nanoparticle size and zeta potential of the NLCs were 171 nm and − 39 mV, respectively. Ciprofloxacin (0.05%, w/v) and rolipram (0.02%) achieved encapsulation percentages of 88% and 96%, respectively, in the nanosystems. The minimum bactericidal concentration of free ciprofloxacin against MRSA increased from 1.95 to 15.63 µg/ml when combined with rolipram, indicating a possible drug-drug interaction that reduced the antibacterial effect. Nanoparticle inclusion promoted the anti-MRSA activity of ciprofloxacin according to time-kill curves. The NLCs were found to be largely internalized into neutrophils and exhibited superior superoxide anion inhibition than free drugs. Retinol incorporation into the nanocarriers facilitated their efficient targeting to the kidneys. The NLCs significantly mitigated MRSA burden and elastase distribution in the organs of MRSA-infected animals, and the greatest inhibition was observed in the kidneys. Bacterial clearance and neutrophil infiltration suppression attenuated the bacteremia-induced cytokine overexpression, leading to an improvement in the survival rate from 22% to 67%. CONCLUSIONS: The dual role of our NLCs endowed them with greater efficacy in treating MRSA bacteremia than that of free drugs. [Image: see text] BioMed Central 2021-02-15 /pmc/articles/PMC7885212/ /pubmed/33588861 http://dx.doi.org/10.1186/s12951-021-00789-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Liao, Chia-Chih Yu, Huang-Ping Yang, Shih-Chun Alalaiwe, Ahmed Dai, You-Shan Liu, Fu-Chao Fang, Jia-You Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice |
title | Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice |
title_full | Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice |
title_fullStr | Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice |
title_full_unstemmed | Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice |
title_short | Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice |
title_sort | multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating mrsa bacteremia in mice |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885212/ https://www.ncbi.nlm.nih.gov/pubmed/33588861 http://dx.doi.org/10.1186/s12951-021-00789-5 |
work_keys_str_mv | AT liaochiachih multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice AT yuhuangping multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice AT yangshihchun multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice AT alalaiweahmed multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice AT daiyoushan multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice AT liufuchao multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice AT fangjiayou multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice |